News

Horizon teams up with AstraZeneca
Enlarge image

BusinessSwedenUK

Horizon teams up with AstraZeneca

23.04.2013 - AstraZeneca has exclusively licenced Horizon Discovery's kinase target programme.

Horizon Discovery and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon's first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types. HD-001 modulates a novel kinase, which is mutated in multiple cancer types including  lung and colon tumours. What is more, the target seems to be crucial in cells with K-RAS mutations, which have been found in 40% of all  cancers that have become resistant to available therapeutics.

The companies said that the preclinical programme have the potential for a  blockbuster drugs as K-RAS defective cells are currently not druggable. Under the terms of the agreement, Horizon will receive undisclosed upfront and preclinical milestone payments, and are eligible for clinical and approval milestones totalling up to US$75m, as well as tiered royalties.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/horizon-teams-up-with-astrazeneca.html

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SANTHERA80.00 CHF6.74%
  • WILEX2.26 EUR1.80%
  • ADDEX4.07 CHF1.75%

FLOP

  • MOLOGEN7.30 EUR-6.41%
  • 4SC1.16 EUR-3.33%
  • EVOLVA1.27 CHF-2.31%

TOP

  • SANTHERA80.00 CHF15.4%
  • MAGFORCE6.47 EUR9.7%
  • CYTOS0.27 CHF8.0%

FLOP

  • WILEX2.26 EUR-27.6%
  • MOLOGEN7.30 EUR-22.3%
  • 4SC1.16 EUR-20.0%

TOP

  • SANTHERA80.00 CHF3709.5%
  • CO.DON2.50 EUR228.9%
  • PAION2.41 EUR190.4%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-68.1%
  • MERCK KGAA64.23 EUR-45.8%

No liability assumed, Date: 21.08.2014